SCC Update: Defining and Managing High-Risk Cutaneous SCC
Course Description
This activity reviews what constitutes high risk, including current staging and other considerations. The roles of Mohs/CCPDMA, nodal staging, adjuvant and neoadjuvant therapy including clinical trials, and anti PD1 systemic therapy for N2 and unresectable disease including success rates, major side-effects, and considerations in determining resectability versus appropriateness for systemic therapy are covered.
Learning Objectives
At the conclusion of this activity, participants should be able to:
This activity reviews what constitutes high risk, including current staging and other considerations. The roles of Mohs/CCPDMA, nodal staging, adjuvant and neoadjuvant therapy including clinical trials, and anti PD1 systemic therapy for N2 and unresectable disease including success rates, major side-effects, and considerations in determining resectability versus appropriateness for systemic therapy are covered.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Apply current prognostic data to identify CSCC patients who are at risk for metastasis and death.
- Determine ideal surgical approach or determine that patient is eligible for systemic therapy as an alternative to surgery.
- Choose appropriate strategies for nodal staging, adjuvant therapy, and surveillance for recurrence.
Event Presenter(s)
Marc Brown, MD
Faculty
Dr. Brown is the Director of Mohs Surgery and Cutaneous Oncology at the University of Rochester Medical Center. Dr. Brown has published over 60 articles and two books and also serves as an editorial reviewer for several major dermatology journals. He lectures and teaches at national meetings focusing on Mohs surgery, melanoma, facial reconstruction, transplant dermatology and challenging and unusual skin cancers.
Faculty
Dr. Brown is the Director of Mohs Surgery and Cutaneous Oncology at the University of Rochester Medical Center. Dr. Brown has published over 60 articles and two books and also serves as an editorial reviewer for several major dermatology journals. He lectures and teaches at national meetings focusing on Mohs surgery, melanoma, facial reconstruction, transplant dermatology and challenging and unusual skin cancers.
Chrysalyne D. Schmults, MD
Faculty
Dr. Chrysalyne Schmults is the Vice-Chair of Surgical Oncology, Department of Dermatology and Director of Mohs and Dermatologic Surgery Center Program at Brigham and Women's Hospital in Boston. As a dermatologist, Mohs surgeon, and former director of a high-risk skin cancer clinic at a major cancer center, Dr. Schmults' research interests stem from her clinical observations and the difficulties she encounters in delivering patient care.
Faculty
Dr. Chrysalyne Schmults is the Vice-Chair of Surgical Oncology, Department of Dermatology and Director of Mohs and Dermatologic Surgery Center Program at Brigham and Women's Hospital in Boston. As a dermatologist, Mohs surgeon, and former director of a high-risk skin cancer clinic at a major cancer center, Dr. Schmults' research interests stem from her clinical observations and the difficulties she encounters in delivering patient care.
Duration
60 minutes
Credits
CME: 1.00 AMA PRA Category 1 Credit™
Accreditation Statement
The American Society for Dermatologic Surgery (ASDS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASDS designates this activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
60 minutes
Credits
CME: 1.00 AMA PRA Category 1 Credit™
Accreditation Statement
The American Society for Dermatologic Surgery (ASDS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASDS designates this activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Copyright 2022 American Society for Dermatologic Surgery (ASDS). All Rights Reserved.